Skip to main content
< Back to news
Image: Esteve.

The Profarma Plan rates Esteve’s R&D&I as “Excellent’’

Esteve's research and innovation activity has been rated ''Excellent'' by the Profarma programme. The pharmaceutical group – that in 2012 established its key units for the discovery of drugs and preclinical development in the Barcelona Science Park – has achieved the highest possible score of this programa uninterruptedly for the last 32 years.


Once more year, Esteve‘s research activity has received the qualification ”Excellent” in the 2019 call of the Profarma (2017-2020) programme, resolved by the Spanish Ministry of Industry, Trade and Tourism. Esteve has been one of the 10 companies rated as “Excellent”, of the 53 evaluated.

This rating allows Esteve to be included in Group A of the Profarma programme, a category that recognizes companies with significant research activity and their own basic or clinical R&D centers. Since 2012, all key units for drug discovery and preclinical development have been located in a 2,400 m2 facility in the Barcelona Science Park.

The fundamental objective of the Profarma Plan is to increase the competitiveness of the pharmaceutical industry in Spain by modernizing the sector and promoting activities that provide greater added value, such as investment in new industrial plants and new production technologies, and by encouraging research, development and innovation. The Profarma Plan rates companies as ”Excellent”, ”Very Good”, ”Good” or ”Acceptable”.